16 Jun 2022 , 09:37 AM
Commenting on the update, Arun Kumar, Founder, said, “The approval from EU-GMP is a significant stepping stone in our journey to build a global biologics CDMO platform that provides end-to-end solutions across the modalities. We have designed our facilities to meet global regulatory standards, and as the other global inspections also come through, we would have all the necessary approvals to serve the global players.
The last few quarters for our CDMO business have been enthusiastic as the company concluded various major contracts. These contracts contributed new service revenues to our business and increased our commercial sales value above $85 million in the peak year. The Global Biologics CDMO space remains thrilling, and we are confident that we will deliver better financial outcomes for Stelis as we progress.”
Stelis’ flagship facility (Unit 2, Bengaluru, India) is an integrated state-of-the-art manufacturing setup. This facility leverages microbial and mammalian platforms for the development and commercialization of biologics and biosimilars in multiple fill-finish formats, including cartridges, devices, pre-filled syringes, liquid, and lyophilized vials.
Stelis’s small-scale cGMP manufacturing facility (Unit 1, Bengaluru, India) supports small-scale commercial and cGMP clinical trial material generation along with initial technology transfer activities across multiple modalities.
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.